Slide 1: 1Q25 Earnings Presentation
1Q25 Earnings Presentation April 24, 2025
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: 1Q25 Main Highlights
1Q25 Main Highlights Sell-Out growth of 6.9%¹ NON-RETAIL MARKET RETAIL MARKET +20.6%² +6.0%³ in 1Q25 in 1Q25 18.9% GROWTH IN CASH FLOW FROM OPERATIONS INTEREST ON CAPITAL APPROVAL OF R$184.7 MILLION (R$0.29/SHARE) Note: (1) Sell-out PPP (Pharmacy Purchase Price) and HPP (Hospital Purchase Price), as
Slide 4: 1Q25 Results (R$ million)
1Q25 Results (R$ million) NET REVENUE R$ 1,080.9 -40.8%1 GROSS MARGIN 47.2%2 -1,390bps3 MARKETING EXPENSES R$ 367.2 +40.0%1 SELLING EXPENSES R$ 262.2 +21.9%1 GENERAL AND ADMINISTRATIVE EXPENSES R$ 86.2 +21.2%1 EBITDA FROM CONTINUING OPERATIONS (R$ 148.5) NET EARNINGS FROM CONTINUING OPERATIONS (R$ 1
Slide 5: 1Q25 Cash Flow (R$ million)
1Q25 Cash Flow (R$ million) 570 348 (147) (74) (347) 1,739 1,740 +19% vs 1Q24 (7,494) (9,234) Gross Cash at the Cash Flow From PP&E Intangibles 1Q25 Free Cash Financing Cash Flow Gross Cash at the Gross Debt at the Net Debt at the end end of 4Q24 Operations Flow end of 1Q25 end of 1Q25 of 1Q25 5 Not
Slide 6: efd
efd harma